Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-05-07

Schrödinger, Inc.

Schrödinger sells computational chemistry and molecular discovery software to pharma and industrial customers and also monetizes the platform through collaborations, equity stakes, and selective internal drug programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Embedment Matters More Than Near-Term Revenue

The realistic upside is a business-model upgrade: a respected simulation suite becomes a more governed, higher-frequency discovery workflow layer. The stock does not need heroic pipeline success, but it does need proof that customers will pay for higher-throughput, trusted AI-enabled workflows.

Analysis

Thesis

If hosted contracts turn Schrödinger from a respected modeling tool into a governed discovery workflow layer, ACV can compound, Bunsen can monetize throughput rather than seats, and collaborator economics can add upside without restoring a balance-sheet-heavy biotech burn.

Last Economy Alignment

Cheaper AI and compute should increase the number of molecular design cycles worth running, and Schrödinger is shifting value capture toward hosted, throughput-based workflows instead of pure seat counts. The main offset is that generic agents could increasingly own the interface and pressure workflow-layer pricing if Schrödinger does not stay the most trusted engine inside enterprise discovery.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.6x (from 5 most recent analyses)

Reasoning

This is mainly a quality-upgrade case, not a heroic clinical-outcome case. The upside comes from Schrödinger becoming more embedded in how discovery teams work: hosted delivery improves durability, Bunsen broadens usage beyond expert users, and trusted workflow governance can make the platform harder to swap out. If that happens, the business can be valued more like specialized scientific software with option value from external programs.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The key risk is strategic, not financial: Schrödinger may remain a high-quality modeling vendor instead of becoming the operating layer for AI-native discovery. If hosted contracts mainly change revenue timing, if Bunsen does not prove measurable throughput gains, or if generic agents weaken the workflow surface, the company can still grow but likely not rerate enough to deliver an outsized five-year outcome.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Q1 2026 results kept the full-year outlook intact while showing 12% ACV growth despite revenue-recognition noise.
Hosted software reached 34% of software revenue in Q1, and management said all new customers and renewals in the quarter adopted hosted contracts.
The summer early-access Bunsen launch was reiterated, making the next few months the first real proof window for AI-driven throughput monetization.
Management added May healthcare-conference appearances, creating near-term update surfaces on timing, pricing, and hosted-transition progress.

Thesis update

No core thesis change. New evidence mainly increases confidence that the hosted shift is a quality upgrade rather than a demand collapse, while keeping Bunsen as the main proof gate.

Forecast update

Quality-adjusted upside improved modestly because hosted adoption is progressing faster and external validation remains active, but the company still lacks enough product proof to justify a much more aggressive value path.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.60

They control validated molecular-design engines and a real workflow footprint inside pharma labs, so cheaper AI and compute should send more discovery work through their system. The risk is that generic agents become the front door and turn Schrödinger into just another engine unless it owns the trusted operating layer.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$21.13

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research